ES2137281T3 - Pirroles sustituidos. - Google Patents

Pirroles sustituidos.

Info

Publication number
ES2137281T3
ES2137281T3 ES94106812T ES94106812T ES2137281T3 ES 2137281 T3 ES2137281 T3 ES 2137281T3 ES 94106812 T ES94106812 T ES 94106812T ES 94106812 T ES94106812 T ES 94106812T ES 2137281 T3 ES2137281 T3 ES 2137281T3
Authority
ES
Spain
Prior art keywords
amino
lower alkyl
aryl
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94106812T
Other languages
English (en)
Inventor
William Harris
Christopher Huw Hill
Geoffrey Lawton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939309602A external-priority patent/GB9309602D0/en
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2137281T3 publication Critical patent/ES2137281T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

LA INVENCION PROPORCIONA COMPUESTOS DE LA FORMULA: EN DONDE R1 REPRESENTA ALQUILO INFERIOR, CICLOALQUILO INFERIOR, ARILO O ARALQUILO INFERIOR, R2 REPRESENTA HIDROGENO, ARILO O ALQUILO INFERIOR OPCIONALMENTE SUSTITUIDO POR HIDROXILO, ACILOXILO, AMINO, MONO(ALQUILO INFERIOR)AMINO, DI(ALQUILO INFERIOR)AMINO, CARBOXILO, ALCOXICARBONILO INFERIOR O AMINOCARBONILO Y M Y N REPRESENTAN 1 O 2. ASI COMO SALES FARMACEUTICAMENTE ACEPTABLES DE COMPUESTOS ACIDOS DE FORMULA I CON BASES Y DE COMPUESTOS BASICOS DE FORMULA I CON ACIDOS, LOS CUALES SE USAN EN EL CONTROL O PREVENCION DE INDISPOSICIONES, ESPECIALMENTE EN EL CONTROL O PREVENCION DE DESORDENES INFLAMATORIOS, INMUNOLOGICOS, ONCOLOGICOS, BRONCOPULMONARES, DERMATOLOGICOS Y CARDIOVASCULARES, EN EL TRATAMIENTO DE ASMA, SIDA O COMPLICACIONES DIABETICAS O PARA LA ESTIMULACION DEL CRECIMIENTO DEL CABELLO.
ES94106812T 1993-05-10 1994-05-02 Pirroles sustituidos. Expired - Lifetime ES2137281T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939309602A GB9309602D0 (en) 1993-05-10 1993-05-10 Substituted pyrroles
GB9403249A GB9403249D0 (en) 1993-05-10 1994-02-21 Substituted pyrroles

Publications (1)

Publication Number Publication Date
ES2137281T3 true ES2137281T3 (es) 1999-12-16

Family

ID=26302877

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94106812T Expired - Lifetime ES2137281T3 (es) 1993-05-10 1994-05-02 Pirroles sustituidos.

Country Status (25)

Country Link
EP (1) EP0624586B1 (es)
JP (1) JP2668818B2 (es)
CN (1) CN1048014C (es)
AT (1) ATE184007T1 (es)
AU (1) AU678435B2 (es)
BG (1) BG98761A (es)
BR (1) BR9401935A (es)
CA (1) CA2121567A1 (es)
CZ (1) CZ112894A3 (es)
DE (1) DE69420310T2 (es)
DK (1) DK0624586T3 (es)
ES (1) ES2137281T3 (es)
FI (1) FI106961B (es)
GR (1) GR3031901T3 (es)
HR (1) HRP940287B1 (es)
HU (1) HU215954B (es)
IL (1) IL109547A (es)
IS (1) IS1690B (es)
LT (1) LT3288B (es)
LV (1) LV11173B (es)
NO (1) NO301230B1 (es)
NZ (1) NZ260475A (es)
RU (1) RU2141960C1 (es)
SI (1) SI0624586T1 (es)
SK (1) SK53594A3 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843935A (en) * 1993-12-07 1998-12-01 Eli Lilly And Company Protein kinase C inhibitors
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
CA2137203C (en) * 1993-12-07 2006-11-28 William Francis Heath Jr. Protein kinase c inhibitors
ATE456367T1 (de) * 1993-12-23 2010-02-15 Lilly Co Eli Proteinkinase c inhibitoren
ATE172463T1 (de) * 1994-08-04 1998-11-15 Hoffmann La Roche Pyrrolocarbazol
US5919946A (en) * 1996-03-20 1999-07-06 Eli Lilly And Company Synthesis of indolylmaleimides
KR100499190B1 (ko) * 1996-03-29 2006-04-17 교와 핫꼬 고교 가부시끼가이샤 육모제
US5859261A (en) * 1997-03-20 1999-01-12 Eli Lilly And Company Synthesis of indolylmaleimides
ES2233691T3 (es) 2000-07-27 2005-06-16 F. Hoffmann-La Roche Ag Derivados de 3-indolil-4-fenil-1h-pirrol-2,5-diona como inhibidores de la glicogen sintasa kinasa-3beta.
CN101703509A (zh) 2001-10-30 2010-05-12 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
CA2393720C (en) 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
BRPI0413439A (pt) 2003-08-08 2006-10-17 Novartis Ag combinações compreendendo estaurosporinas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
SK75289A3 (en) * 1988-02-10 1998-05-06 Hoffmann La Roche Substituted pyrroles, their use for producing a drug, and the drug on their base
DE3833008A1 (de) * 1988-09-29 1990-04-05 Goedecke Ag Pyrrolocarbozol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles

Also Published As

Publication number Publication date
LTIP1927A (en) 1994-11-25
FI106961B (fi) 2001-05-15
IL109547A (en) 1998-07-15
EP0624586A1 (en) 1994-11-17
NZ260475A (en) 1996-02-27
NO941682D0 (no) 1994-05-06
LT3288B (en) 1995-06-26
BG98761A (en) 1995-03-31
HU9401298D0 (en) 1994-08-29
LV11173A (lv) 1996-04-20
AU6055594A (en) 1994-11-17
DE69420310D1 (de) 1999-10-07
HU215954B (hu) 1999-03-29
IS1690B (is) 1998-04-20
CN1103402A (zh) 1995-06-07
IS4162A (is) 1994-11-11
JPH06329672A (ja) 1994-11-29
LV11173B (en) 1996-06-20
CZ112894A3 (en) 1994-12-15
IL109547A0 (en) 1994-08-26
NO301230B1 (no) 1997-09-29
BR9401935A (pt) 1995-03-07
AU678435B2 (en) 1997-05-29
FI942158A0 (fi) 1994-05-10
DK0624586T3 (da) 2000-03-27
HUT71492A (en) 1995-11-28
SK53594A3 (en) 1995-02-08
EP0624586B1 (en) 1999-09-01
HRP940287B1 (en) 2000-02-29
JP2668818B2 (ja) 1997-10-27
GR3031901T3 (en) 2000-02-29
ATE184007T1 (de) 1999-09-15
CA2121567A1 (en) 1994-11-11
DE69420310T2 (de) 2000-04-13
CN1048014C (zh) 2000-01-05
FI942158A7 (fi) 1994-11-11
NO941682L (no) 1994-11-11
HRP940287A2 (en) 1996-12-31
SI0624586T1 (en) 1999-12-31
RU2141960C1 (ru) 1999-11-27

Similar Documents

Publication Publication Date Title
ES2137281T3 (es) Pirroles sustituidos.
ECSP941096A (es) Procedimiento para la preparacion de un derivado indol
MX9206008A (es) Inhibidores de enzima proteolitica, derivados de sacarina 2-substituida.
ATE502941T1 (de) Hemmer der menschlichen phosphatidyl-inositol-3- kinase delta
IL172942A0 (en) Pyrazoloisoquinoline derivatives as kinase inhibitors
DK1438052T3 (da) Quinazolin-4-oner af inhibitorer som human phosphatidylinositol 3-kinase delta
ATE218336T1 (de) Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom
NO992821L (no) Ketobenzamider som calpain-inhibitorer
GB0209891D0 (en) Novel compounds
MY110104A (en) Saccharin derivative proteolytic enzyme inhibitors
DE50209015D1 (de) NEUE VERWENDUNG VON 2-Ä2-Ethoxy-5-(4-methyl-piperazin-1-sulfonyl)-phenylÜ-5-methyl-7-propyl-3H-imidazoÄ5,1-fÜÄ1,2,4Ütriazin-4-on
DE60015508T2 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
NO975028L (no) Piperazinoderivater som neurokininantagonister
ES2160164T3 (es) Himenialdisina y sus derivados, procedimiento para producir un intermedio para su sintesis, y dicho intermedio.
ATE337005T1 (de) Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis
AR033779A1 (es) Compuestos utiles en la enfermedad de reflujo
EP2036891A3 (en) Isoquinoline inhibitors of P38
ES2182890T3 (es) Sintesis de acidos 4-arilo-2-hidroxitetronicos opticamente puros.
SV1994000023A (es) Pirroles sustituidos ref. ran 4070/90
DE59810675D1 (de) Oxirancarbonsäuren für die behandlung von diabetes
CU22713A3 (es) Procedimiento de obtencion del compuesto 4-(2-cloro-3-ciano-fenil)-1,4-dihidro-2,6-dimetilpiridin-3,5-dicarboxilato de isopropilo y 2-metoxietilo
CA2394230A1 (en) Novel stromelysin inhibitors
GT199300033A (es) Procedimiento para la preparacion de un derivado indol
SE9901273D0 (sv) Novel compounds

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 624586

Country of ref document: ES